Banque Cantonale Vaudoise Has $1.84 Million Stake in IQVIA Holdings Inc. (NYSE:IQV)

Banque Cantonale Vaudoise lessened its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 37.1% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 7,779 shares of the medical research company’s stock after selling 4,596 shares during the period. Banque Cantonale Vaudoise’s holdings in IQVIA were worth $1,844,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. 1832 Asset Management L.P. raised its stake in IQVIA by 472.3% during the 2nd quarter. 1832 Asset Management L.P. now owns 456,335 shares of the medical research company’s stock worth $96,487,000 after buying an additional 376,595 shares during the period. Renaissance Technologies LLC bought a new position in shares of IQVIA in the second quarter valued at $70,610,000. Impax Asset Management Group plc increased its position in shares of IQVIA by 19.3% during the second quarter. Impax Asset Management Group plc now owns 1,635,201 shares of the medical research company’s stock worth $344,998,000 after acquiring an additional 264,555 shares in the last quarter. Canada Pension Plan Investment Board lifted its position in IQVIA by 6.6% in the 2nd quarter. Canada Pension Plan Investment Board now owns 3,403,488 shares of the medical research company’s stock valued at $719,634,000 after acquiring an additional 211,653 shares in the last quarter. Finally, D. E. Shaw & Co. Inc. lifted its holdings in shares of IQVIA by 285.1% in the second quarter. D. E. Shaw & Co. Inc. now owns 268,552 shares of the medical research company’s stock valued at $56,783,000 after purchasing an additional 198,808 shares in the last quarter. 89.62% of the stock is owned by institutional investors.

Insiders Place Their Bets

In related news, insider Eric Sherbet sold 1,300 shares of the business’s stock in a transaction on Tuesday, August 27th. The stock was sold at an average price of $246.33, for a total transaction of $320,229.00. Following the sale, the insider now directly owns 19,536 shares in the company, valued at approximately $4,812,302.88. The trade was a 6.24 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 1.60% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on IQV shares. Leerink Partners reiterated an “outperform” rating and issued a $248.00 target price (down previously from $260.00) on shares of IQVIA in a research note on Tuesday. TD Cowen decreased their price objective on shares of IQVIA from $270.00 to $255.00 and set a “buy” rating for the company in a research note on Friday, November 1st. JPMorgan Chase & Co. cut their target price on IQVIA from $279.00 to $240.00 and set an “overweight” rating on the stock in a research note on Tuesday, November 5th. StockNews.com raised IQVIA from a “hold” rating to a “buy” rating in a research report on Wednesday. Finally, Argus raised IQVIA to a “strong-buy” rating in a research report on Wednesday, July 31st. Four equities research analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, IQVIA has a consensus rating of “Moderate Buy” and an average target price of $256.50.

IQVIA Stock Up 1.6 %

IQV opened at $194.38 on Thursday. IQVIA Holdings Inc. has a 12 month low of $187.62 and a 12 month high of $261.73. The company has a market cap of $35.28 billion, a PE ratio of 25.51, a price-to-earnings-growth ratio of 1.98 and a beta of 1.51. The company has a current ratio of 0.81, a quick ratio of 0.81 and a debt-to-equity ratio of 1.76. The company has a 50 day moving average of $224.22 and a 200 day moving average of $227.56.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.